Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

PEG drugs: an overview.

R B Greenwald1

  • 1Enzon Inc., 20 Kingsbridge Road, Piscataway, NJ 08854-3969, USA. richard.greenwald@enzon.com

Journal of Controlled Release : Official Journal of the Controlled Release Society
|August 8, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Drug delivery systems employing 1,6-elimination: releasable poly(ethylene glycol) conjugates of proteins.

Bioconjugate chemistry·2001
Same author

20-O-acylcamptothecin derivatives: evidence for lactone stabilization.

The Journal of organic chemistry·2000
Same author

Camptothecin delivery systems: the utility of amino acid spacers for the conjugation of camptothecin with polyethylene glycol to create prodrugs.

Anti-cancer drug design·2000
Same author

Poly(ethylene glycol) conjugated drugs and prodrugs: a comprehensive review.

Critical reviews in therapeutic drug carrier systems·2000
Same author

Drug delivery systems based on trimethyl lock lactonization: poly(ethylene glycol) prodrugs of amino-containing compounds.

Journal of medicinal chemistry·2000
Same author

Drug delivery systems employing 1,4- or 1,6-elimination: poly(ethylene glycol) prodrugs of amine-containing compounds.

Journal of medicinal chemistry·1999

High molecular weight poly(ethylene glycol) (PEG) conjugates, particularly PEG 40000, have revived the field of PEG drug conjugates, leading to a clinical candidate for cancer therapy.

Area of Science:

  • Bioconjugation Chemistry
  • Pharmaceutical Sciences
  • Drug Delivery Systems

Background:

  • Low molecular weight poly(ethylene glycol) (PEG) conjugates (<20000 Da) have not yielded clinically approved products despite extensive research over 20 years.
  • A recent resurgence in PEGylated anticancer drug conjugates has occurred, driven by the use of higher molecular weight PEGs (>20000 Da).

Purpose of the Study:

  • To review the advancements in high molecular weight PEG drug conjugates.
  • To highlight the successful development of a clinical candidate using PEG 40000.
  • To explore potential applications of high molecular weight PEG prodrug strategies.

Main Methods:

  • Comparative analysis of low vs. high molecular weight PEG conjugates.
  • In vivo testing using established tumor models.

Related Experiment Videos

  • Application of high molecular weight PEG prodrug strategies to amino-containing drugs.

    • Main Results:

    • Higher molecular weight PEGs, especially PEG 40000 (estimated half-life of 8-9 h in mice), have enabled a renaissance in PEG drug conjugate development.
    • Meaningful in vivo testing has led to the identification of a clinical candidate.
    • Successful application of high molecular weight PEG prodrug strategies to amino-containing drugs has been demonstrated.

    Conclusions:

    • High molecular weight PEG conjugates represent a successful strategy for small molecule drug delivery, particularly in oncology.
    • PEG 40000 is a promising component for developing effective PEG drug conjugates.
    • Further applications in protein modification and drug delivery are anticipated.